GlassScriptPhysician profile
Navid Hafez
NPI 1740505007
$13,506.00
in general payments reported to CMS, 2019-2025
21 companies · $2,115 in 2025
The $2,115 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $1,159 · 2022: $952 · 2023: $3,585 · 2024: $4,690 · 2025: $2,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,040 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,764 · Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,040.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,764.46 |
| Food and Beverage | $585.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $4,632.12 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $3,840.00 | 2024-2025 | |
| Pfizer INC. | $2,200.00 | 2023 | |
| Boehringer Ingelheim Pharma Gmbh & Co.Kg | $1,158.56 | 2020 | |
| F. Hoffmann-La Roche Ag | $1,005.04 | 2019 | |
| Emd Serono, INC. | $287.74 | 2023-2025 | Tepmetko |
| Jazz Pharmaceuticals INC. | $127.34 | 2025 | |
| Galvanize Therapeutics, INC | $103.53 | 2024 | Aliya System |
| Daiichi Sankyo INC. | $84.79 | 2022 | |
| Genentech USA, INC. | $46.49 | 2024 | |
| Array Biopharma INC | $20.39 | 2025 | Mektovi, Braftovi, Tukysa |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navid Hafez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.